The study also showed daily energy intake was inversely correlated with estimated glucose disposal rate (eGDR), a marker for insulin resistance (IR).
Higher intake of fat, but not carbohydrates, is associated with increased insulin resistance (IR) and adverse vascular profile in patients with type 1 diabetes (T1D), according to a study published in the European Journal of Nutrition.
According to the study authors, this is the first report demonstrating dietary intake is linked to IR and an adverse vascular profile in patients with T1D.
To come to this finding, the authors pooled baseline data from 3 randomized controlled trials (RCTs), using estimated glucose disposal rate (eGDR) as a marker for IR. Multivariate nutrient density substitution models were used to examined the association between macronutrient composition and IR and vascular biomarkers, including tumor necrosis factor-α (TNF- α), fibrinogen, tissue factor (TF) activity, and plasminogen activator inhibitorn-1 (PAI-1).
A total of 107 patients were included in the current analysis. About half were male, and the mean (SD) age was 29 (6) years. The authors noted that participants with lower eGDR were older with a longer T1D duration, higher insulin requirements, and an adverse vascular profile (P < .05).
Participants self-reported their intake using 2 methods, a 48-hour weighed food diary and the Dietary Instrument for Nutrition Education (DINE) Food Frequency Questionnaire (FFQ). From this information, fat intake was categorized into 3 groups with frequency of fat consumption converted into a score:
Patients were also stratified by eGDR tertiles, with lower eGDR values, measured in mg/kg/min, conferring higher degrees of IR; eGDR tertiles were < 5.1, 5.1-8.6, and ≥ 8.7 mg/kg/min/.
The authors found that daily energy intake was inversely correlated with eGDR.
Compared with patients with lower degrees of IR, patients with increased IR had statistically significant (P < .001) higher total energy intake (kcal/d).
Patients with increased IR also consumed a higher absolute and proportional amount of fat, with means (SD) of 47.6% (18.6%), 30.4% (8.1%), and 25.8% (10.4%), respectively (P < .001).
After adjusting for total energy intake, age, sex, and T1D duration, the authors found that increased carbohydrate intake offset by an isoenergetic decrease in fat was associated with higher eGDR (β = 0.103; 95% CI, 0.044-0.163).
However, increased dietary fat at the expense of dietary protein intake was associated with lower eGDR (β = −0.119; 95% CI, −0.199 to −0.040).
Additionally, replacing fat with 5% isoenergetic amount of carbohydrate resulted in decreased vascular biomarkers (P < .05).
“Future research is required to explore the impact of diet in greater detail with a specific focus on individual dietary components, including diet quality, processing, and timing, thus enabling more accurate and personalized individually dietary management,” the authors concluded. “A different dietary assessment tool such as 7-day food diary may also be required to better display dietary patterns in this group.”
Reference
Kietsiriroje N, Shah H, Zare M, et al. Dietary fat intake is associated with insulin resistance and an adverse vascular profile in patients with T1D: a pooled analysis. Eur J Nutr. Published online December 10, 2022. doi:10.1007/s00394-022-03070-z
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Study Highlights Significant Increases in Utilization, Spending on DMD Drugs in Medicaid
May 17th 2024The findings add to recent research on the growing utilization, expenditure, and prices of Duchenne muscular dystrophy (DMD) therapies in the current landscape, an area health care policy could potentially address.
Read More
Perioperative Nivolumab Boosts NSCLC Survival: CheckMate 77T Trial
May 16th 2024This interim analysis of the CheckMate 77T trial, outcomes were compared between adult patients receiving neoadjuvant nivolumab plus chemotherapy or neoadjuvant chemotherapy plus placebo for resectable non–small cell lung cancer (NSCLC).
Read More